Environmental influences affecting genetically susceptible individuals seem to contribute significantly to the development of Parkinson's disease (PD). Xenobiotic exposure including transitional metal deposition into vulnerable CNS regions appears to interact with PD genes. Such exposure together with mitochondrial dysfunction evokes a destructive cascade of biochemical events, including oxidative stress and degeneration of the sensitive dopamine (DA) production system in the basal ganglia. Recent research indicates that the substantia nigra degeneration can be decelerated by treatment with iron binding compounds such as deferiprone. Interestingly compounds known to decrease PD risk including caffeine, niacin, nicotine and salbutamol also possess iron binding properties. Adequate function of antioxidative mechanisms in the vulnerable brain cells can be restored by acetylcysteine supplementation to normalize intracellular glutathione activity. Other preventive measures to reduce deterioration of dopaminergic neurons may involve life-style changes such as intake of natural antioxidants and physical exercise. Further research is recommended to identify therapeutic targets of the proposed interventions, in particular protection of the DA biosynthesis by oxygen radical scavengers and iron binding agents.

Department of Clinical Physiology Capio St Görans Hospital Stockholm Sweden

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University Praha 2 Czech Republic

Department of Radiology 1st Faculty of Medicine Charles University Praha 2 Czech Republic

General University Hospital Prague Prague Czech Republic

Inland Norway University of Applied Sciences Elverum Norway

Institute of Environmental Medicine Karolinska Institutet Solna Sweden

Research Department Innlandet Hospital Trust Brumunddal Norway

See more in PubMed

Aaseth J, Alexander J, Wannag A. Effect of thiocarbamate derivatives on copper, zinc, and mercury distribution in rats and mice. Arch Toxicol. 1981;48:29–39. PubMed

Aaseth J, Korkina LG, Afanas’ev IB. Hemolytic activity of copper sulfate as influenced by epinephrine and chelating thiols. Acta Pharmacol Sin. 1998;19:203–206. PubMed

Abeliovich A, Gitler AD. Defects in trafficking bridge Parkinson’s disease pathology and genetics. Nature. 2016;539:207–216. PubMed

Acosta-Cabronero J, Cardenas-Blanco A, Betts MJ, Butryn M, Valdes-Herrera JP, Galazky I, Nestor PJ. The whole-brain pattern of magnetic susceptibility perturbations in Parkinson’s disease. Brain. 2017;140:118–131. PubMed

Ahlskog JE. Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology. 2011;77:288–294. PubMed PMC

Alehagen U, Johansson P, Bjornstedt M, Rosen A, Post C, Aaseth J. Relatively high mortality risk in elderly Swedish subjects with low selenium status. Eur J Clin Nutr. 2016;70:91–96. PubMed PMC

Alehagen U, Johansson P, Aaseth J, Alexander J, Brismar K. Increase in insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 1 after supplementation with selenium and coenzyme Q10. A prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. PLoS ONE. 2017;12:e0178614. PubMed PMC

Al-Saif FA, Refat MS. Ten metal complexes of vitamin B 3/niacin: Spectroscopic, thermal, antibacterial, antifungal, cytotoxicity and antitumor studies of Mn(II), Fe(III), Co(II), Ni(II), Cu(II), Zn(II), Pd(II), Cd(II), Pt(IV) and Au(III) complexes. J Mol Struct. 2012;1021:40–52.

Anderson DW, Bradbury KA, Schneider JS. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism. Eur J Neurosci. 2008;28:610–617. PubMed

Andjelković M, Van Camp J, De Meulenaer B, Depaemelaere G, Socaciu C, Verloo M, Verhe R. Iron-chelation properties of phenolic acids bearing catechol and galloyl groups. Food Chem. 2006;98:23–31.

Asanuma M, Miyazaki I, Ogawa N. Dopamine- or l-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotox Res. 2003;5:165–176. PubMed

Asanuma M, Miyazaki I, Ogawa N. Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases. Curr Pharm Des. 2004;10:695–700. PubMed

Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. 2016;15:1257–1272. PubMed

Barbosa JH, Santos AC, Tumas V, Liu M, Zheng W, Haacke EM, Salmon CE. Quantifying brain iron deposition in patients with Parkinson’s disease using quantitative susceptibility mapping, R2 and R2. Magn Reson Imaging. 2015;33:559–565. PubMed

Barnham KJ, Bush AI. Metals in Alzheimer’s and Parkinson’s diseases. Curr Opin Chem Biol. 2008;12:222–228. PubMed

Barranco Quintana JL, Allam MF, Del Castillo AS, Navajas RF. Parkinson’s disease and tea: a quantitative review. J Am Coll Nutr. 2009;28:1–6. PubMed

Barreto GE, Iarkov A, Moran VE. Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson’s disease. Front Aging Neurosci. 2014;6:340. PubMed PMC

Becker C, Jick SS, Meier CR. NSAID use and risk of Parkinson disease: a population-based case–control study. Eur J Neurol. 2011;18:1336–1342. PubMed

Berg D, et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson’s disease. Brain. 2005;128:3000–3011. PubMed

Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington, clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20:415–455. PubMed

Blackinton J, et al. Post-transcriptional regulation of mRNA associated with DJ-1 in sporadic Parkinson disease. Neurosci Lett. 2009;452:8–11. PubMed PMC

Bohnen NI, Muller ML, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, Albin RL. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. 2009;73:1670–1676. PubMed PMC

Brodacki B, Staszewski J, Toczylowska B, Kozlowska E, Drela N, Chalimoniuk M, Stepien A. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett. 2008;441:158–162. PubMed

Bus JS, Gibson JE. Paraquat: model for oxidant-initiated toxicity. Environ Health Perspect. 1984;55:37–46. PubMed PMC

Chen H, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol. 2003;60:1059–1064. PubMed

Chinta SJ, Kumar JM, Zhang H, Forman HJ, Andersen JK. Up-regulation of gamma-glutamyl transpeptidase activity following glutathione depletion has a compensatory rather than an inhibitory effect on mitochondrial complex I activity: implications for Parkinson’s disease. Free Radic Biol Med. 2006;40:1557–1563. PubMed PMC

Costa J, Lunet N, Santos C, Santos J, Vaz-Carneiro A. Caffeine exposure and the risk of Parkinson’s disease: a systematic review and meta-analysis of observational studies. JAD. 2010;20(Suppl 1):S221–238. PubMed

Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B. Parkinson’s disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol. 2009;169:919–926. PubMed PMC

Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39:889–909. PubMed

Deleidi M, Gasser T. The role of inflammation in sporadic and familial Parkinson’s disease. CMLS. 2013;70:4259–4273. PubMed PMC

Devos D, et al. Targeting chelatable iron as a therapeutic modality in Parkinson’s disease. Antioxid Redox Signal. 2014;21:195–210. PubMed PMC

Double KL, Reyes S, Werry EL, Halliday GM. Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog Neurobiol. 2010;92:316–329. PubMed

Duncan C, White AR. Copper complexes as therapeutic agents. Metallomics. 2012;4:127–138. PubMed

Dusek P, Roos PM, Litwin T, Schneider SA, Flaten TP, Aaseth J. The neurotoxicity of iron, copper and manganese in Parkinson’s and Wilson’s diseases. J Trace Elem Med Biol. 2015;31:193–203. PubMed

Dzamko N, Geczy CL, Halliday GM. Inflammation is genetically implicated in Parkinson’s disease. Neuroscience. 2015;302:89–102. PubMed

Ellingsen DG, Thomassen Y, Rustad P, Molander P, Aaseth J. The time-trend and the relation between smoking and circulating selenium concentrations in Norway. J Trace Elem Med Biol. 2009;23:107–115. PubMed

Etminan M, Suissa S. NSAID use and the risk of Parkinson’s disease. Curr Drug Saf. 2006;1:223–225. PubMed

Fang F, Chen H, Feldman AL, Kamel F, Ye W, Wirdefeldt K. Head injury and Parkinson’s disease: a population-based study. Mov Disord. 2012;27:1632–1635. PubMed

Fang F, Wirdefeldt K, Jacks A, Kamel F, Ye W, Chen H. CNS infections, sepsis and risk of Parkinson’s disease. Int J Epidemiol. 2012;41:1042–1049. PubMed PMC

Fatima N. Complexation, stability and stoichiometry of iron (III) with salbutamol (active ingredient of asthma drug Ventolin®) Pak J Biol Sci. 2012;2:91–98.

Fazary AE. Metal complexes of nicotine: a group of negligible compounds. Abha: Pelagia Research Library; 2017.

Fisher BE, et al. The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson’s disease. Arch Phys Med Rehabil. 2008;89:1221–1229. PubMed PMC

Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology. 2010;74:995–1002. PubMed PMC

Gao HM, Liu B, Hong JS. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci. 2003;23:6181–6187. PubMed PMC

Genoud S, et al. Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson’s disease brain. Metallomics. 2017;9:1447–1455. PubMed PMC

Global Burden of Disease Cancer C et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3:524–548. PubMed PMC

Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL. The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2008;23:631–640. PubMed

Hamburger SA, McCay PB. Spin trapping of ibuprofen radicals: evidence that ibuprofen is a hydroxyl radical scavenger. Free Radic Res Commun. 1990;9:337–342. PubMed

Hare DJ, Double KL. Iron and dopamine: a toxic couple. Brain. 2016;139:1026–1035. PubMed

Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology. 2010;210:453–469. PubMed PMC

Iacono D, Geraci-Erck M, Rabin ML, Adler CH, Serrano G, Beach TG, Kurlan R. Parkinson disease and incidental Lewy body disease: just a question of time? Neurology. 2015;85:1670–1679. PubMed PMC

Jasinska AJ, Zorick T, Brody AL, Stein EA. Dual role of nicotine in addiction and cognition: a review of neuroimaging studies in humans. Neuropharmacology. 2014;84:111–122. PubMed PMC

Kalia LV, Lang AE. Parkinson disease in 2015: evolving basic, pathological and clinical concepts in PD Nature reviews. Neurology. 2016;12:65–66. PubMed

Kalinderi K, Bostantjopoulou S, Fidani L. The genetic background of Parkinson’s disease: current progress and future prospects. Acta Neurol Scand. 2016;134:314–326. PubMed

Kelton MC, Kahn HJ, Conrath CL, Newhouse PA. The effects of nicotine on Parkinson’s disease. Brain Cogn. 2000;43:274–282. PubMed

Kennedy TP, Rao NV, Noah W, Michael JR, Jafri MH, Jr, Gurtner GH, Hoidal JR. Ibuprofen prevents oxidant lung injury and in vitro lipid peroxidation by chelating iron. J Clin Investig. 1990;86:1565–1573. PubMed PMC

Klivenyi P, et al. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J Neurosci. 2000;20:1–7. PubMed PMC

Langston JW, Ballard P. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson’s disease. Can J Neurol Sci. 1984;11:160–165. PubMed

Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, Chen RC. Environmental risk factors and Parkinson’s disease: a case-control study in Taiwan. Neurology. 1997;48:1583–1588. PubMed

Lucchini RG, Martin CJ, Doney BC. From manganism to manganese-induced parkinsonism: a conceptual model based on the evolution of exposure. NeuroMol Med. 2009;11:311–321. PubMed

Malenka RC, Nestler EJ, Hyman SE (2009) In: Molecular neuropharmacology: a foundation for clinical neuroscience, 2nd ed. McGraw-Hill Medical, New York, p. 234

Martin-Bastida A, et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease. Sci Rep. 2017;7:1398. PubMed PMC

Mattson MP. Interventions that improve body and brain bioenergetics for Parkinson’s disease risk reduction and therapy. J Parkinson’s Dis. 2014;4:1–13. PubMed

McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology. 1988;38:1285–1291. PubMed

Meister A, Anderson ME. Glutathione. Ann Rev Biochem. 1983;52:711–760. PubMed

Mittal S, et al. β2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson’s disease. Science. 2017;357:891–898. PubMed PMC

Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, Schrag A. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol. 2012;72:893–901. PubMed PMC

Ossowska K, et al. Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson’s disease. Neuroscience. 2006;141:2155–2165. PubMed

Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson’s disease. J Neural Transm. 1997;104:661–677. PubMed

Peng J, Peng L, Stevenson FF, Doctrow SR, Andersen JK. Iron and paraquat as synergistic environmental risk factors in sporadic Parkinson’s disease accelerate age-related neurodegeneration. J Neurosci. 2007;27:6914–6922. PubMed PMC

Pezzoli G, Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology. 2013;80:2035–2041. PubMed

Poewe W, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. PubMed

Postuma RB, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology. 2012;79:651–658. PubMed PMC

Postuma RB, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–1601. PubMed

Postuma RB, et al. Caffeine as symptomatic treatment for Parkinson disease (Cafe-PD): a randomized trial. Neurology. 2017;89:1795–1803. PubMed PMC

Power JH, Blumbergs PC. Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol. 2009;117:63–73. PubMed

Qi H, Li S. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson’s disease. Geriatr Gerontol Int. 2014;14:430–439. PubMed

Qi Z, Miller GW, Voit EO. Rotenone and paraquat perturb dopamine metabolism: a computational analysis of pesticide toxicity. Toxicology. 2014;315:92–101. PubMed PMC

Quik M. Smoking, nicotine and Parkinson’s disease. Trends Neurosci. 2004;27:561–568. PubMed

Rahimmi A, Khosrobakhsh F, Izadpanah E, Moloudi MR, Hassanzadeh K. N-acetylcysteine prevents rotenone-induced Parkinson’s disease in rat: an investigation into the interaction of parkin and Drp1 proteins. Brain Res Bull. 2015;113:34–40. PubMed

Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology. New York: Churchill Livingstone; 2003.

Roberts NA, Robinson PA. Copper chelates of antirheumatic and anti-inflammatory agents: their superoxide dismutase-like activity and stability. Br J Rheumatol. 1985;24:128–136. PubMed

Robinson R. In the pipeline-Parkinson’s disease: why a common asthma drug could be a disease modifier for Parkinson’s disease. Neurology. 2017;17:1–23.

Ross GW, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. Jama. 2000;283:2674–2679. PubMed

Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: biochemical role as a component of glutathione peroxidase. Science. 1973;179:588–590. PubMed

Roy S, Preston JE, Hider RC, Ma YM. Glucosylated deferiprone and its brain uptake: implications for developing glucosylated hydroxypyridinone analogues intended to cross the blood–brain barrier. J Med Chem. 2010;53:5886–5889. PubMed

Smeyne RJ, Jackson-Lewis V. The MPTP model of Parkinson’s disease Brain research. Mol Brain Res. 2005;134:57–66. PubMed

Stokes AH, Hastings TG, Vrana KE. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res. 1999;55:659–665. PubMed

Stokholm MG, et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case–control study. Lancet Neurol. 2017;16:789–796. PubMed

Tanner CM, et al. Environmental factors and Parkinson’s disease: a case-control study in China. Neurology. 1989;39:660–664. PubMed

Tanner CM, et al. Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect. 2011;119:866–872. PubMed PMC

Tansey MG, Goldberg MS. Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 2010;37:510–518. PubMed PMC

Teismann P, Vila M, Choi DK, Tieu K, Wu DC, Jackson-Lewis V, Przedborski S. COX-2 and neurodegeneration in Parkinson’s disease. Ann N Y Acad Sci. 2003;991:272–277. PubMed

Toulorge D, Guerreiro S, Hild A, Maskos U, Hirsch EC, Michel PP. Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+ FASEB J. 2011;25:2563–2573. PubMed

Trepanier G, Furling D, Puymirat J, Mirault ME. Immunocytochemical localization of seleno-glutathione peroxidase in the adult mouse brain. Neuroscience. 1996;75:231–243. PubMed

Trist BG, et al. Accumulation of dysfunctional SOD1 protein in Parkinson’s disease is not associated with mutations in the SOD1 gene. Acta Neuropathol. 2018;135:155–156. PubMed

Vivekanantham S, Shah S, Dewji R, Dewji A, Khatri C, Ologunde R. Neuroinflammation in Parkinson’s disease: role in neurodegeneration and tissue repair. Int J Neurosci. 2015;125:717–725. PubMed

Volpicelli-Daley LA, et al. G2019S-LRRK2 expression augments alpha-synuclein sequestration into inclusions in neurons. J Neurosci. 2016;36:7415–7427. PubMed PMC

Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology. 2007;69:1836–1842. PubMed

Wakade C, Chong R. A novel treatment target for Parkinson’s disease. J Neurol Sci. 2014;347:34–38. PubMed

Wang H, Cheng E, Brooke S, Chang P, Sapolsky R. Over-expression of antioxidant enzymes protects cultured hippocampal and cortical neurons from necrotic insults. J Neurochem. 2003;87:1527–1534. PubMed

Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13:1045–1060. PubMed PMC

Wullner U, et al. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones. NeuroReport. 1996;7:921–923. PubMed

Xu K, Di Luca DG, Orru M, Xu Y, Chen JF, Schwarzschild MA. Neuroprotection by caffeine in the MPTP model of Parkinson’s disease and its dependence on adenosine A2A receptors. Neuroscience. 2016;322:129–137. PubMed PMC

Yang F, Trolle Lagerros Y, Bellocco R, Adami HO, Fang F, Pedersen NL, Wirdefeldt K. Physical activity and risk of Parkinson’s disease in the Swedish National March Cohort. Brain. 2015;138:269–275. PubMed

Zhang J, Fitsanakis VA, Gu G, Jing D, Ao M, Amarnath V, Montine TJ. Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. J Neurochem. 2003;84:336–346. PubMed

Zhang J, et al. Nicotine attenuates beta-amyloid-induced neurotoxicity by regulating metal homeostasis. FASEB J. 2006;20:1212–1214. PubMed

Zhang L, Yagnik G, Jiang D, Shi S, Chang P, Zhou F. Separation of intermediates of iron-catalyzed dopamine oxidation reactions using reversed-phase ion-pairing chromatography coupled in tandem with UV-visible and ESI-MS detections. J Chromatograph B Anal Technol Biomed Life Sci. 2012;911:55–58. PubMed PMC

Cerebral Iron Deposition in Neurodegeneration